Caliciviridae Infections clinical trials
The registry lists 20 studies for Caliciviridae Infections across 7 countries. 2 are recruiting or about to start. 17 of them are mainly about Caliciviridae Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04.
Get an email when these change. Save the Caliciviridae Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Vaxart (8) · National Vaccine and Serum Institute, China (3) · Children's Hospital Medical Center, Cincinnati (2) · IRCCS Sacro Cuore Don Calabria di Negrar (1) · Institut Pasteur du Cambodge (1) · Region Zealand (1) · Romark Laboratories L.C. (1) · InThera Inc. Korea (1)
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Aug 2027A Study to Evaluate INT101 in Healthy Adults for the Prevention of Norovirus Gastroenteritis · InThera Inc. Korea
Who these studies take
Of the 2 Caliciviridae Infections studies recruiting now, 0 (0%) set no upper age limit and 2 (100%) stop at 75 or younger. 1 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (100%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (50%) | 1 (50%) |
| 18 | 1 (50%) | 1 (50%) |
| 30 | 2 (100%) | 2 (100%) |
| 40 | 2 (100%) | 2 (100%) |
| 50 | 1 (50%) | 1 (50%) |
| 65 | 1 (50%) | 1 (50%) |
| 75 | 1 (50%) | 1 (50%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 20 studies, recruiting or not: 70% stop at 75 or younger and 65% at 65; 40% take children; 5% are for women only and 0% for men only; 80% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 20 of 20. search them.
- A Study to Evaluate INT101 in Healthy Adults for the Prevention of Norovirus GastroenteritisRecruitingNCT07818629Phase 11 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- Norovirus Prevalence and Fecal Microbiome Characterization Through Metagenomic and Metatranscriptomic AnalysesActive, not recruitingNCT07866469Not applicable1 country
- A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years OldCompletedNCT06944717Phase 11 country
- A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing InfantsCompletedNCT07254728Phase 11 country
- Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine,Recombinant (Hansenula Polymorpha)CompletedNCT05916326Phase 31 country
- Norovirus Challenge StudyCompletedNCT05212168Phase 1/21 country
- A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy VolunteersCompletedNCT05626803Phase 21 country
- A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult VolunteersCompletedNCT05213728Phase 11 country
- Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus VaccinesCompletedNCT04875676Phase 1/21 country
- Admission Pattern Among Children With Gastro-intestinal Infections Before and During the Covid-19 PandemicCompletedNCT062116211 country
- Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus VaccineCompletedNCT04854746Phase 11 country
- Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)Status unknownNCT04941261Phase 21 country
- Safety & Immunogenicity Study of Ad5 Based Oral Norovirus VaccinesCompletedNCT03897309Phase 11 country
- A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent VaccineCompletedNCT04188691Phase 11 country
- Human Breastmilk in Young Children With Norovirus Infection of the GutTerminatedNCT02371538Not applicable1 country
- Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge ModelCompletedNCT03721549Phase 11 country
- Norovirus Bivalent-Vaccine Efficacy StudyCompletedNCT01609257Phase 1/21 country
- Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)CompletedNCT01435811Phase 11 country
- Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in ChildrenCompletedNCT00302640Phase 2/3